{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T15:23:47Z","timestamp":1780673027940,"version":"3.54.1"},"reference-count":14,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T00:00:00Z","timestamp":1631491200000},"content-version":"vor","delay-in-days":12,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Dermatology"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background\/Objective<\/jats:title><jats:p>Dupilumab is highly effective in treating atopic dermatitis (AD). However, some patients experience difficulties with dupilumab therapy, such as inadequate clinical response, failure to achieve long\u2010term disease control, or adverse events (AEs). Our objective is to assess inadequate response and AEs occurring in children on dupilumab therapy for AD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This is a retrospective cohort study of children on dupilumab for AD. Collected variables included patient demographics, medical histories, and dupilumab therapy characteristics. Response analysis was conducted in those with \u22653\u00a0months of dupilumab therapy: primary poor responders were defined as those whose EASI scores did not decrease by &gt;50%, and secondary poor responders were those who initially responded but had significant AD flares while on therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We included 200 patients on dupilumab for AD in our cohort; 192 received \u22653\u00a0months of therapy and were included in our response analysis. Twelve children experienced inadequate primary response, and 4 were secondary poor responders. Four of these 16 children discontinued therapy due to inadequate response.<\/jats:p><jats:p>The most common dupilumab\u2010associated AEs were facial erythema (n\u00a0=\u00a024, 12.0%) and injection\u2010site reactions (n\u00a0=\u00a024, 12.0%). Female sex was significantly associated with experiencing injection\u2010site reactions, and prior hospitalization was significantly associated with HSV infection on dupilumab. Eight patients discontinued therapy due to an AE.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>A small but significant number of patients experienced treatment difficulties while on dupilumab. The risk of inadequate response to dupilumab and dupilumab\u2010associated AEs should be discussed thoroughly with patients and their families prior to initiation.<\/jats:p><\/jats:sec>","DOI":"10.1111\/pde.14799","type":"journal-article","created":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T10:52:02Z","timestamp":1631530322000},"page":"1178-1184","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Experience using dupilumab for pediatric atopic dermatitis at a tertiary care c enter: Inadequate response and adverse events"],"prefix":"10.1111","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5324-8507","authenticated-orcid":false,"given":"Paige L.","family":"McKenzie","sequence":"first","affiliation":[{"name":"Section of Dermatology The Children\u2019s Hospital of Philadelphia  Philadelphia PA USA"},{"name":"University of Texas Southwestern Medical Center  Dallas TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sneha","family":"Rangu","sequence":"additional","affiliation":[{"name":"Section of Dermatology The Children\u2019s Hospital of Philadelphia  Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Treat","sequence":"additional","affiliation":[{"name":"Section of Dermatology The Children\u2019s Hospital of Philadelphia  Philadelphia PA USA"},{"name":"University of Pennsylvania Perelman School of Medicine  Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3289-446X","authenticated-orcid":false,"given":"Leslie","family":"Castelo\u2010Soccio","sequence":"additional","affiliation":[{"name":"Section of Dermatology The Children\u2019s Hospital of Philadelphia  Philadelphia PA USA"},{"name":"University of Pennsylvania Perelman School of Medicine  Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,9,13]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2014.09.008"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2017.08.005"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314768"},{"key":"e_1_2_6_5_1","unstructured":"EasiScore.com\u202f: easily calculate the eczema area and severity index to determine atopic dermatitis severity.https:\/\/www.easiscore.com\/. Accessed April 27 2021."},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2019.07.020"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01951"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555\u2010018\u20100258\u2010x"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257\u2010019\u201000436\u20108"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S163814"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2017.11.031"},{"key":"e_1_2_6_12_1","unstructured":"Adult Clinical Trial Safety Profile | DUPIXENT\u00ae (dupilumab).https:\/\/www.dupixenthcp.com\/atopicdermatitis\/efficacy\u2010safety\/safety\u2010clinical\u2010trial. Accessed May 11 2021."},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.06.026"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.06.1003"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/jan.13818"}],"container-title":["Pediatric Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pde.14799","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/pde.14799","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pde.14799","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T20:09:04Z","timestamp":1696536544000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/pde.14799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10.1111\/pde.14799"],"URL":"https:\/\/doi.org\/10.1111\/pde.14799","archive":["Portico"],"relation":{},"ISSN":["0736-8046","1525-1470"],"issn-type":[{"value":"0736-8046","type":"print"},{"value":"1525-1470","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"2021-09-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}